Innovative clinical-stage biotech company

Evexta Bio, formerly Diaccurate, is a biopharmaceutical company exploring the new frontiers of oncology in search of daring novel therapeutic approaches with the potential to save lives. Now in the clinic, the French biotech is currently developing two proprietary therapeutic assets with novel mechanisms of action across several indications:

• Rupitasertib, a first-in-class oral double node PAM pathway inhibitor targeting S6K and AKT1/AKT3 to address resistance to endocrine therapies in breast cancer. Clinical (phase 1) and preclinical (xenograft models) data supports the clinical development of rupitasertib in combination with a SERD, in ESR1 mutant ER+ HER2- advanced breast cancer, in a Phase 1b trial which is expected to start in 2026.
• EVX020, an antibody-drug conjugate program using a first-in-class KIF20A kinesin inhibitor as payload in hematological and solid tumors.

Founded by Truffle Capital, Evexta Bio has forged alliances with leaders in academia and industry, including CNRS, Paoli-Calmettes Institute (Marseille, France) and Merck KGaA (Darmstadt, Germany). The company is supported by seasoned management team, board of directors and medical advisory board.